Compare Essex Property Trust, Inc. (ESS) vs TG Therapeutics Inc (TGTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Essex Property Trust, Inc. vs TG Therapeutics Inc — how do they compare? Essex Property Trust, Inc. trades at $271.57 (market cap $17.26B), while TG Therapeutics Inc trades at $55.37 (market cap $8.16B). The key difference: Essex Property Trust, Inc. is far larger — about 2.1× TG Therapeutics Inc's market cap, and Essex Property Trust, Inc. pays a 3.86% dividend while TG Therapeutics Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Essex Property Trust, Inc. for 111 Days and TG Therapeutics Inc for 16 Days on average.
| ESS | TGTX | |
|---|---|---|
Market Cap | $17.26B | $8.16B |
Volume | 454,464 | 1,735,121 |
Sector | Real Estate | Health |
52-Week High | $298.33 | $59.06 |
52-Week Low | $239.61 | $26.94 |
Typical Hold Time | 111 Days | 16 Days |
Enterprise Value | $23.86B | $8.37B |
Dividend Yield | 3.86% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ESS trades at $268.58, up 0.2% on the day, with a bearish technical signal from moving averages but neutral oscillators. The company reported mixed quarterly earnings, missing in Q4 2025 and Q2 2026 but beating in Q1 2026, with revenue reaching $1.89 billion in 2025. Analyst consensus is a Buy with a $303.41 price target, though the stock faces headwinds from high valuation multiples and legal uncertainties recently resolved.
The outlook for ESS is cautiously optimistic, supported by strong operational efficiency and raised full-year guidance, but risks include elevated debt levels and sensitivity to real estate market cycles. Investment appeal hinges on execution of growth strategies amid economic fluctuations.
TG Therapeutics (TGTX) trades at $53.34, up 0.74% today, but faces bearish technical signals despite strong profitability metrics like a 55.22% net income margin. Recent earnings misses and a shareholder investigation create headwinds, though revenue growth and a high analyst buy consensus of 84.62% suggest underlying strength. The stock's current price is near key support at $52, with resistance at $54.
The outlook is mixed: robust revenue growth and institutional buying support upside toward the $80.50 consensus target, but earnings misses and legal risks pose challenges. Investors should weigh the company's MS therapy momentum against execution and regulatory uncertainties for balanced risk-reward assessment.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Essex Property Trust, Inc.
Essex Property Trust owns a portfolio of 253 apartment communities with over 62,000 units and is developing three additional properties with 571 units. The company focuses on owning large, high-quality properties on the West Coast in the urban and suburban submarkets of Southern California, Northern California, and Seattle.
Read more on ESS →About TG Therapeutics Inc
TG Therapeutics is a fully integrated biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases. Its cornerstone product, BRIUMVI (ublituximab-xiiy), is a glycoengineered monoclonal antibody approved for relapsing forms of multiple sclerosis. The company is currently executing a 'pipeline-in-a-product' strategy, expanding BRIUMVI into new delivery methods and indications while advancing a broader portfolio of autoimmune and oncology candidates.
Read more on TGTX →
